<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01194934</url>
  </required_header>
  <id_info>
    <org_study_id>SNOXA12C101</org_study_id>
    <secondary_id>2010-020937-14</secondary_id>
    <nct_id>NCT01194934</nct_id>
  </id_info>
  <brief_title>NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers</brief_title>
  <acronym>SNOXA12C101</acronym>
  <official_title>A Single Center, Open-label, Repeated Dose, Phase I Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics and the Effect on Mobilization of Hematopoietic Stem Cells of NOX-A12 Alone and in Combination With Filgrastim</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noxxon Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charité Research Organization GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Noxxon Pharma AG</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the second clinical study of NOX-A12. This study intends to provide information on
      the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of repeated
      intravenous doses of NOX-A12 (2.0 and 4.0 mg/kg/d) alone and to compare the mobilization of
      hematopoietic stem cells (HSC) obtained with NOX-A12 alone with that obtained in combination
      with filgrastim in healthy subjects. A single center, open-label, repeated dose study design
      is selected to best address the study objectives.The results from this study will establish
      the basis for further development of NOX-A12 in lymphoma patients undergoing autologous
      hematopoietic stem cell transplantation
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety Study, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>To determine the safety and tolerability of repeated doses of NOX-A12 alone and in combination with filgrastim in healthy subjects.</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetics of repeated doses of NOX-A12 alone and in combination with filgrastim in healthy subjects.</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To quantify the mobilization of HSCs in peripheral blood after repeated doses of NOX-A12 alone, of filgrastim alone and after the combination of NOX-A12 with filgrastim.</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: 2.0 mg/kg NOX-A12 IV every day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B: 4.0 mg/kg NOX-A12 IV every day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.
Group C: 5 µg/kg filgrastim SC every day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.
Group D: Safe and efficacious dose of NOX-A12 IV in combination with filgrastim SC for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOX-A12</intervention_name>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOX-A12</intervention_name>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOX-A12 in combination with Filgrastim</intervention_name>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects of any ethnic origin.

          -  Body weight between 50 and 100 kg (extremes included).

          -  Healthy as determined by medical history, physical examination, vital signs, 12-lead
             electrocardiogram, and clinical laboratory parameters.

          -  Females of non-childbearing potential, defined as surgically sterile or
             post-menopausal.

          -  Males willing to use 2 means of contraceptive methods for at least 3 months after
             test substance administration.

          -  Normal lung function (FVC and FEV1 at least 80% of predicted values) at screening.

        Exclusion Criteria:

          -  Intake of vitamin A derivates or retinoids within 30 days prior to the start of drug
             administration.

          -  History of thrombosis.

          -  Chronic infection or acute infection or fever within the last 8 weeks prior to the
             start of drug administration.

          -  Subjects with a splenomegaly.

          -  Participation in another clinical study within three months prior to the start of
             drug administration.

          -  Blood donation (&gt;100 ml) or a comparable blood loss within three months prior to the
             start of drug administration.

          -  Subjects who, in the investigator's opinion, may not be capable of following the
             study schedule for any reason.

          -  Subjects having already received G-CSF in the past.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Wagner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Research Organisation GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Hueser, PhD</last_name>
    <phone>0049 30 450 539</phone>
    <phone_ext>233</phone_ext>
    <email>Andreas.Hueser@charite-research.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité Research Organisation GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10589</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hueser, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Frank Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <lastchanged_date>September 16, 2010</lastchanged_date>
  <firstreceived_date>September 2, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Priv.-Doz. Dr. med. Frank Wagner</name_title>
    <organization>Charité Research Organisation GmbH</organization>
  </responsible_party>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>SDF-1</keyword>
  <keyword>L-oligonucleotide Aptamer</keyword>
  <keyword>Spiegelmer</keyword>
  <keyword>Hematopoietic Stem Cells</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
</clinical_study>
